undamentalytics Newsletter
Sign in

Supernus Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Supernus Pharmaceuticals, Inc.'s operations generated $47.3m of cash; it spent $1.3m on capital projects, leaving free cash flow of $46.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−33−36−47−58−2435671151291431381271171111724788
Depreciation and amortisation111111287718338685809252
Stock-based pay0−0023468111517181827283336
Capital spending01121222133—01111
Free cash flow−33−37−48−60−253265113128140135—1161111714687
Free cash flow after stock pay−33−37−48−62−282859104117126118—99841431351
Shares issued001012122612447127153829

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AXSM vs SUPNCORT vs SUPNHRMY vs SUPN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Supernus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Supernus Pharmaceuticals, Inc.